Overview

Laidlaw Capital Markets focuses exclusively on healthcare, giving our research analysts the focus and foresight to know what our clients care about. Our Research Department consists of highly skilled professionals whose timely, insightful, and targeted research is a core strength of the firm. Our analysts pride themselves on their ability to identify compelling investment opportunities for our clients by discovering high-quality, undervalued healthcare companies before they are recognized by the broader market. Our analysts’ in-depth expertise and strong industry relationships enable them to remain at the forefront of the market trends impacting the companies they follow. By clearly and effectively presenting their investment ideas, while also evaluating expectations for both performance and risk, the firm’s research professionals help investors make sound decisions in today’s volatile markets.

Research Team

Yale Jen
Yale JenManaging Director, Healthcare Equity Analyst
Dr. Jen joined Laidlaw & Co. in September 2013 as Managing Director, Biotechnology Analyst. He has over ten years of Wall Street healthcare analyst experience. Prior to joining Laidlaw, he was a Senior Equity Analyst at Roth Capital Partners focusing on biotechnology since February 2012; and before that – a Senior Equity Analyst focusing on biotechnology and China healthcare at Maxim Group since November 2007. Prior, he was an associate analyst at Rodman and Renshaw and Thomas Weisel Partners covering large as well as mid to small cap biotechnology and specialty pharmaceutical companies. His investment views have been cited in the Wall Street Journal, Bloomberg, Thomson Reuters and Dow Jones Newswire. Before joining Wall Street, Yale spent several years with KPMG Corporate Finance Life Sciences Group and Genesis Group Associates focusing on mergers and acquisitions of healthcare assets, as well as on pipeline optimization for pharmaceutical and biotechnology clients. Dr. Jen received his Ph.D. in molecular biology from Cornell Medical School and his MBA from Rutgers University with a concentration in finance. He holds FINRA licenses: 7, 63, 86 and 87.
Francois Brisebois
Francois BriseboisHealthcare Equity Analyst
Francois Brisebois joined Laidlaw in May 2015 as an Associate Research Analyst covering specialty pharmaceuticals and biotechnology. Prior to joining Laidlaw, he was VP Institutional Sales at Summer Street Research Partners. He received his M.Sc. in Pharmaceutical Sciences (Pharmacology) from the University of Montreal where he wrote his thesis on the role of E3-Ligase Parkin in mitochondrial quality control in a cardiotoxicity model to anthracyclines. Francois also co-authored “Formation of mitochondrial-derived vesicles is an active and physiologically relevant mitochondrial quality control process in the cardiac system” published in The Journal of Physiology. He received his BA in Molecular Biology from Colgate University, where he co-captained the Ice Hockey team. He holds FINRA licenses: 7, 63, 86 and 87.
Olivia Lamb
Olivia LambAssociate Biotechnology Equity Analyst
Olivia Lamb joined Laidlaw & Company as an Associate Research Analyst covering biotechnology and specialty pharmaceuticals. Prior to joining Laidlaw, she conducted preclinical research developing and investigating genetic mouse models of autism at the Matthew Anderson Lab of Neurology under Harvard Medical School within Beth Israel Deaconess Medical Center, Boston. She simultaneously received her B.S. in Biology with a concentration in Neuroscience and Minor in Management from Emmanuel College, Boston where she received distinction in the field of Biology for her thesis on developing Cre-dependent viral vectors to map neural substrates underlying comorbid aggression in autism spectrum disorders. Prior to that, Olivia worked in the Preclinical Orthopedics division of Sanofi Genzyme where she developed in-vitro models of chondrogenesis and conducted cell-based screening assays to rate different compounds’ ability to inhibit angiogenesis.